BIOMAT Database Logo BIOMAT Database Logo

AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. 1996

A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Hoechst Marion Roussel, Cincinnati, Ohio 45215, USA.

Interleukin-1 (IL-1) -alpha and -beta are potent regulators of inflammatory responses. The naturally occurring interleukin-1 receptor antagonist (IL-1ra) is effective in vitro and in vivo in modulating biological responses to IL-1. We have previously reported the discovery of IL-1 antagonist peptides from the search of phage display libraries. Further characterization of this group of peptides has led to a 15-mer, AF12198, Ac-FEWTPGWYQJYALPL-NH2 (J represents the unnatural amino acid, 2-azetidine-1-carboxylic acid), with both in vitro and in vivo IL-1 antagonist activity. AF12198 selectively binds the human type I IL-1 receptor but not the human type II receptor or the murine type I receptor. In vitro, AF12198 inhibits IL-1-induced IL-8 production by human dermal fibroblasts with a half-maximal inhibition concentration or IC50 of 25 nM and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression by endothelial cells with an IC50 of 9 nM. When given as an intravenous infusion to cynomolgus monkeys, AF12198 blocks ex vivo IL-1 induction of IL-6 and down modulates in vivo induction of IL-6. This is the first small molecule to show IL-1 receptor antagonist activity in vivo.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012795 Sialoglycoproteins Glycoproteins which contain sialic acid as one of their carbohydrates. They are often found on or in the cell or tissue membranes and participate in a variety of biological activities. Polysialoglycoprotein,Sialoglycopeptide,Sialoglycopeptides,Sialoglycoprotein,Sialoprotein,Sialoproteins,Polysialoglycoproteins

Related Publications

A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.
February 1995, Proceedings of the National Academy of Sciences of the United States of America,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Soluble type-I interleukin-1 receptor blocks chicken IL-1 activity.
May 2001, Developmental and comparative immunology,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Interleukin 1 receptor antagonist blocks somnogenic and pyrogenic responses to an interleukin 1 fragment.
May 1992, Proceedings of the National Academy of Sciences of the United States of America,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes.
May 1992, Blood,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils.
October 1991, The Journal of biological chemistry,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Characterization of a low molecular weight isoform of IL-1 receptor antagonist.
August 1998, Journal of immunology (Baltimore, Md. : 1950),
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
October 1995, European journal of immunology,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.
June 1991, The Journal of biological chemistry,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I.
September 1993, Cytokine,
A L Akeson, and C W Woods, and L C Hsieh, and R A Bohnke, and B L Ackermann, and K Y Chan, and J L Robinson, and S D Yanofsky, and J W Jacobs, and R W Barrett, and T L Bowlin
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
November 1991, Immunology today,
Copied contents to your clipboard!